Please login to the form below

Not currently logged in

Frank Pieters leaves Teva to lead Cipla’s respiratory business

Will head up attempt to capitalise on the expiry of major pharma patents, such as that of GSK's Advair

Frank Pieters has left Teva Pharmaceutical to join India-based generics company Cipla as head of its European region and global respiratory business.

Pieters was most recently senior VP Southern Europe at Israel-based Teva – the largest generics company in the world.

His latest move signals an intent from Cipla to take advantage of the patent expiries for leading respiratory products, including GlaxoSmithKline's (GSK) Advair, which Cipla has a generic version.

“With [Pieters] at the helm, Cipla would like to capture the huge commercial upside of 30 years experience in Cipla's respiratory medicine; both in emerging and regulated markets,” said Dr Yusuf Hamied, chairman and managing director, Cipla.

“This appointment signals Cipla's strengthening of senior management positions and also illustrates Cipla's desire for senior on-ground talent in overseas markets to build its product portfolio and brand.”

During his time at Teva, Pieters also served as senior VP global biogenerics and global respiratory commercial business and he was also a member of the TEVA-Lonza Joint Steering Committee.

From 1989 to 2004, he held several senior positions at GSK, including VP and general manager.

6th July 2012


Featured jobs

Subscribe to our email news alerts


Add my company

C+D has been informing, supporting and championing community pharmacy for more than 150 years. As an award-winning multi-media publisher we...

Latest intelligence

Access to orphan drugs for rare cancers in EU28
Revisiting Instagram for pharma
In pharma, Instagram usage is increasing because it offers so many benefits to engage with patients and HCPs...
The one multichannel question you must ask
There is a question every marketer should ask when designing a multichannel communications strategy...